New York Life Investment Management LLC Makes New $1.72 Million Investment in BioLife Solutions, Inc. $BLFS

New York Life Investment Management LLC bought a new position in BioLife Solutions, Inc. (NASDAQ:BLFS) in the third quarter, Holdings Channel.com reports. The firm bought 44,383 shares of the medical equipment provider’s stock, valued at approximately $1,724,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BLFS. Oregon Public Employees Retirement Fund grew its stake in BioLife Solutions by 7.8% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 9,685 shares of the medical equipment provider’s stock valued at $376,000 after purchasing an additional 700 shares during the last quarter. ProShare Advisors LLC acquired a new position in shares of BioLife Solutions in the third quarter valued at about $683,000. Transmarket Holdings LP acquired a new position in shares of BioLife Solutions in the third quarter valued at about $5,366,000. Yousif Capital Management LLC raised its stake in shares of BioLife Solutions by 4.9% in the third quarter. Yousif Capital Management LLC now owns 11,097 shares of the medical equipment provider’s stock worth $431,000 after purchasing an additional 520 shares during the last quarter. Finally, Kings Path Partners LLC acquired a new stake in shares of BioLife Solutions during the third quarter worth about $644,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

BLFS has been the topic of a number of recent research reports. Maxim Group lowered BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Monday, September 21st. William Blair set a $31.00 price target on shares of BioLife Solutions in a research report on Thursday, July 23rd. Weiss Ratings upgraded shares of BioLife Solutions from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. Finally, Wall Street Zen cut shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Saturday, July 25th. One analyst has rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, BioLife Solutions presently has an average rating of “Hold” and a consensus price target of $31.38.

BioLife Solutions Stock Performance

NASDAQ BLFS remained flat at $38.61 on Friday. BioLife Solutions, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $39.76. The stock has a market capitalization of $1.89 billion, a P/E ratio of 33.28 and a beta of 1.82. The company’s 50 day simple moving average is $37.93 and its two-hundred day simple moving average is $28.64.

BioLife Solutions Company Profile

BioLife Solutions, Inc. develops and supplies products and services used in the development and commercial production of cell and gene therapies and other biologic medicines. Its offerings support the handling, preservation, storage and distribution of sensitive biological materials. The company’s products include CryoStor and HypoThermosol preservation media, as well as CellSeal bags designed for cryogenic storage. BioLife also provides temperature-controlled storage and repository services for biological materials through its SciSafe business.